Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.55 USD | -4.97% | -12.30% | -28.63% |
Mar. 27 | Health Care Jumps as Upward Momentum Builds -- Health Care Roundup | DJ |
Mar. 27 | Transcript : Syros Pharmaceuticals, Inc., 2023 Earnings Call, Mar 27, 2024 |
Business Summary
Number of employees: 117
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Gene Control Medicines
100.0
%
| 23 | 100.0 % | 15 | 100.0 % | -36.65% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 23 | 100.0 % | 15 | 100.0 % | -36.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Conley Chee
CEO | Chief Executive Officer | 54 | 21-09-26 |
Jason Haas
DFI | Director of Finance/CFO | 56 | 21-10-11 |
David Roth
CTO | Chief Tech/Sci/R&D Officer | 61 | 15-12-06 |
Gerald E. Quirk
ADM | Chief Administrative Officer | 56 | 16-08-31 |
Karen Hunady
IRC | Investor Relations Contact | - | 22-09-30 |
Lisa Roberts
HRO | Human Resources Officer | - | 11-12-31 |
Kristin Stephens
PRN | Corporate Officer/Principal | 51 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Srini Akkaraju
BRD | Director/Board Member | 56 | 17-06-11 |
Tim Tyson
BRD | Director/Board Member | 71 | 22-09-15 |
Marsha Fanucci
BRD | Director/Board Member | 70 | 15-10-18 |
Deborah Dunsire
BRD | Director/Board Member | 61 | 21-09-08 |
Peter Wirth
CHM | Chairman | 73 | 17-01-29 |
Richard Young
FOU | Founder | 70 | 11-11-08 |
S. Gail Eckhardt
BRD | Director/Board Member | 66 | 20-09-07 |
Andrew Oh
BRD | Director/Board Member | 53 | 22-09-15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 25,660,038 | 25,404,156 ( 99.00 %) | 0 | 99.00 % |
Company contact information
Syros Pharmaceuticals, Inc.
35 CambridgePark Drive 4th floor
02140-2325, Cambridge
+617 744 1340
http://www.syros.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.03% | 152M | |
+9.16% | 45.97B | |
+53.69% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |
- Stock
- Equities
- Stock Syros Pharmaceuticals, Inc. - Nasdaq
- Company Syros Pharmaceuticals, Inc.